Eclipse Re Ltd. (Series 2017-01A)
The Artemis Catastrophe Bond and Insurance-linked Securities Deal Directory aims to provide a one-stop resource for information on every cat bond and ILS transaction we hold information on. The content of this Deal Directory is provided as is and there will be some omissions. Help us to keep these cat bond and ILS transaction summaries up to date by contacting us if you see an error or omission that you can correct.
Eclipse Re Ltd. (Series 2017-01A) - At a glance:
- Issuer / SPV: Eclipse Re Ltd. (Series 2017-01A)
- Cedent / Sponsor: Unknown
- Placement / structuring agent/s: Rewire Securities acted as bookrunner.
- Risk modelling / calculation agents etc: Unknown
- Risks / Perils covered: Unknown
- Size: $20m
- Trigger type: Unknown
- Ratings: NR
- Date of issue: Apr 2017
Eclipse Re Ltd. (Series 2017-01A) - Full details
This Eclipse Re Ltd. 2017-01A issuance is the first private series of catastrophe bond notes to be issued through the Eclipse Re Ltd. collatewralized reinsurance note platform.
This first issuance saw special purpose insurer and segregate accounts company Eclipse Re Ltd. issuing a $20 million single tranche of Series 2017-01A notes which are due 1st April 2019, suggesting this covers a two-year collateralized reinsurance arrangement.
The $20 million of Eclipse Re 2017-01A notes were privately placed with qualified investors, a service that will have been provided via Rewire Securities which will have acted as the bookrunner for the transaction.
Horseshoe Group also acted as the listing sponsor, the first time it has done so through its Horseshoe Corporate Services entity, with the Eclipse Re note program and Series 2017-01A notes both listed on the Bermuda Stock Exchange (BSX).
Further details are not available, due to the private nature of this ILS transaction.
The Artemis Catastrophe Bond & Insurance-Linked Securities Deal Directory is copyright © Steve Evans Ltd. Reproduction or publication without permission is not permitted. Use of this information within a commercial product, or for profit, without a license is strictly prohibited. Contact us if you would like to use this content or to discuss licensing.